225 results on '"Rota, Rossella"'
Search Results
2. HDAC3 genetic and pharmacologic inhibition radiosensitizes fusion positive rhabdomyosarcoma by promoting DNA double-strand breaks
3. Antitumour effects of SFX-01 molecule in combination with ionizing radiation in preclinical and in vivo models of rhabdomyosarcoma
4. DNA repair in tumor radioresistance: insights from fruit flies genetics
5. Gamma-Secretase Inhibitors Downregulate the Profibrotic NOTCH Signaling Pathway in Recessive Dystrophic Epidermolysis Bullosa
6. MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting
7. Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models
8. Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
9. Epigenetic remodelling in human hepatocellular carcinoma
10. Miswired Enhancer Logic Drives a Cancer of the Muscle Lineage
11. Gamma-secretase inhibitors down-regulate the pro-fibrotic Notch signaling pathway in recessive dystrophic epidermolysis bullosa
12. Notch Signaling in Pediatric Soft Tissue Sarcoma
13. Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma
14. Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
15. Aberrant Function of the C-Terminal Tail of HIST1H1E Accelerates Cellular Senescence and Causes Premature Aging
16. Small heat-shock protein HSPB3 promotes myogenesis by regulating the lamin B receptor
17. Histone hyperacetylation disrupts core gene regulatory architecture in rhabdomyosarcoma
18. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial
19. Genomic and Epigenetic Changes Drive Aberrant Skeletal Muscle Differentiation in Rhabdomyosarcoma
20. Heat Shock Proteins: Important Helpers for the Development, Maintenance and Regeneration of Skeletal Muscles
21. Supplemental Figures 1 through 10 from PAX3–FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability
22. Supplemental Methods and Legends from PAX3–FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability
23. Supplemental Tables from PAX3–FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability
24. Data from PAX3–FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability
25. Genomic and Epigenetic Changes Drive Aberrant Skeletal Muscle Differentiation in Rhabdomyosarcoma
26. Chemical genomics reveals histone deacetylases are required for core regulatory transcription
27. Data from SNAI2-Mediated Repression of BIM Protects Rhabdomyosarcoma from Ionizing Radiation
28. Supplementary Tables 1-5 from SNAI2-Mediated Repression of BIM Protects Rhabdomyosarcoma from Ionizing Radiation
29. Supplementary Materials, Methods, and References from SNAI2-Mediated Repression of BIM Protects Rhabdomyosarcoma from Ionizing Radiation
30. Data from MMSET Is Highly Expressed and Associated with Aggressiveness in Neuroblastoma
31. Supplementary Methods, Figures 1-10 from MMSET Is Highly Expressed and Associated with Aggressiveness in Neuroblastoma
32. DNA Damage Response Gene Signature as Potential Treatment Markers for Oral Squamous Cell Carcinoma
33. Spermine oxidase induces DNA damage and sensitizes fusion negative rhabdomyosarcoma cells to irradiation
34. A MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting
35. The botanical drug PBI-05204, a supercritical CO2 extract of Nerium oleander, sensitizes alveolar and embryonal rhabdomyosarcoma to radiotherapy in vitro and in vivo
36. MicroRNA profiling of paediatric AML with FLT-ITD or MLL-rearrangements: Expression signatures and in vitro modulation of miR-221-3p and miR-222-3p with BRD4/HATs inhibitors
37. Translational Implications for Radiosensitizing Strategies in Rhabdomyosarcoma
38. Radioresistance in rhabdomyosarcomas: Much more than a question of dose
39. Hyperactive Akt1 Signaling Increases Tumor Progression and DNA Repair in Embryonal Rhabdomyosarcoma RD Line and Confers Susceptibility to Glycolysis and Mevalonate Pathway Inhibitors
40. Abstract 668: A MYOD-SKP2 axis boosts oncogenic properties of fusion negative rhabdomyosarcoma and is counteracted by neddylation inhibition in vitro and in vivo
41. MET Inhibition Sensitizes Rhabdomyosarcoma Cells to NOTCH Signaling Suppression
42. Additional file 3 of Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
43. Additional file 2 of Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
44. Additional file 1 of Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
45. New Insights on the Nuclear Functions and Targeting of FAK in Cancer
46. Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant
47. Review for "Identification and targeting of a HES1‐YAP1‐CDKN1C functional interaction in fusion‐negative rhabdomyosarcoma"
48. DNMT3A and DNMT3B Targeting as an Effective Radiosensitizing Strategy in Embryonal Rhabdomyosarcoma
49. MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells
50. The botanical drug PBI-05204, a supercritical CO2 extract of Nerium oleander, sensitizes alveolar and embryonal rhabdomyosarcoma to radiotherapy in vitro and in vivo.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.